Ethoximod Pharmacokinetics In Healthy Subjects - Trial NCT06361212
Access comprehensive clinical trial information for NCT06361212 through Pure Global AI's free database. This Phase 1 trial is sponsored by Longevity Inc. and is currently Completed. The study focuses on Psoriasis. Target enrollment is 65 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Longevity Inc.
Timeline & Enrollment
Phase 1
Sep 01, 2022
Jan 12, 2024
Primary Outcome
Peak plasma concentration (Cmax),Time to peak plasma concentration (Tmax),The lowest plasma concentration (Cmin),Half-life (t1/2),Number of adverse events and number of participants with adverse events
Summary
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and
 pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are:
 
 1. to evaluate the safety and tolerance of Ethoximod in healthy subjects after single or
 repeated doses.
 
 2. to assess the pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects
 after single or repeated doses.
 
 3. to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy
 subjects Participants will receive test tablets or placebo at the indicated date and
 collect blood samples.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06361212
Non-Device Trial